Health Highlights: April 14, 2021
FDA to Set Limits on Toxic Elements in Baby Food
Limits on toxic elements such as arsenic, lead and mercury in baby food will be proposed by the U.S. Food and Drug Administration over the next few years, but adhering to them will be voluntary for manufacturers.
The FDA made the announcement two months after a congressional report said baby food products from several of the largest makers were "tainted" with toxic heavy metals, CBS News reported.
"We recognize that Americans want zero toxic elements in the foods eaten by their babies and young children. In reality, because these elements occur in our air, water and soil, there are limits to how low these levels can be," the FDA said in a statement.
It said it's goal with its multi-year strategy called Closer to Zero "is to reduce the levels of arsenic, lead, cadmium and mercury in these foods to the greatest extent possible."
The agency said it will assess the science, set maximum acceptable levels and monitor baby food makers' compliance. Regulators plan to draft a standard for maximum levels of lead in baby food by April 2022 and for arsenic by April 2024, with a final ruling on lead coming by April 2024 followed by one on arsenic. The agency said it would also gather and review data on cadmium and mercury.
"It's good that the FDA is finally proposing to propose limits on metals in baby food," Scott Faber, senior vice president for government affairs at the Environmental Working Group, said in a statement released Tuesday. "Setting draft levels will send a powerful signal to the food industry to do better. But proposing to propose is not the same as setting mandatory standards that baby food companies must meet. Parents should not have to wait – and Congress should not wait, but instead set interim levels in the law that companies must meet right away."
Gerber, the country's biggest baby food manufacturer, said in a statement that it welcomed the opportunity to work with the FDA to make "the food supply even safer for infants and young children."
Experts say that exposure to heavy metals over time can cause neurodevelopmental disabilities, including autism, in children, CBS News reported.
Moderna COVID-19 Vaccine 90% Effective Six Months After Second Dose
Moderna's two-dose COVID-19 vaccine continues to provide strong protection against the new coronavirus six months after people have received their second shot, the company reported Tuesday.
It said that findings from its late-stage trial follow-up showed that six months after the second dose, the vaccine remained 90% effective against all cases of COVID-19 and 95% effective against severe cases of the disease, the Washington Post reported.
Moderna also said that it's testing vaccine candidates that target specific variants of the new coronavirus, including the B.1.351 variant first detected in South Africa. Some studies have suggested that the variant can escape immunity provided by current vaccines.
One of the candidates combines the vaccine targeting the B.1.351 variant with Moderna's original shot, which the company said "provided the broadest level of immunity" when tested on mice, the Post reported.
The company said its early results on vaccines that target specific variants would be submitted for peer-reviewed publication, the Post reported.
© 2021 HealthDay. All rights reserved.
Posted: April 2021
Read this next
MONDAY, May 10, 2021 -- Taking nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen doesn't make COVID-19 worse or more deadly, a new study finds. When the pandemic...
MONDAY, May 10, 2021 (American Heart Association News) -- It's not surprising that babies born prematurely may face more health issues than those who were carried to term. But...
MONDAY, May 10, 2021 -- Organ transplant recipients remain vulnerable to infection with the new coronavirus even after receiving both doses of two-dose vaccines, new research...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.